Clinical trial
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
NCT00095953 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00095953 |
|---|---|
| Title | SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma |
| Official title | A Phase II Study of SB-715992 (NSC 727990) in Previously Untreated Patients With Metastatic or Recurrent Malignant Melanoma |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Drug |
| Interventions | ispinesib |
| Enrollment | 17 |
| Start date | Nov 1, 2004 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2008 |
| First posted | Nov 9, 2004 |
| Last update posted | May 17, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: